Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VERV

Verve Therapeutics (VERV) Stock Price, News & Analysis

Verve Therapeutics logo

About Verve Therapeutics Stock (NASDAQ:VERV)

Advanced Chart

Key Stats

Today's Range
$11.13
$11.13
50-Day Range
$10.91
$11.38
52-Week Range
$2.86
$11.40
Volume
N/A
Average Volume
3.94 million shs
Market Capitalization
$992.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.57
Consensus Rating
Hold

Company Overview

Verve Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

VERV MarketRank™: 

Verve Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 488th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verve Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Verve Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Verve Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Verve Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.83) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verve Therapeutics is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verve Therapeutics is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Verve Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.52% of the float of Verve Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Verve Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Verve Therapeutics has recently decreased by 67.44%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Verve Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Verve Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.52% of the float of Verve Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Verve Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Verve Therapeutics has recently decreased by 67.44%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Verve Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    Only 2 people have searched for VERV on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • MarketBeat Follows

    Only 8 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Verve Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.30% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verve Therapeutics' insider trading history.
Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VERV Stock News Headlines

Analysts Set Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target at $14.57
Buffett, Gates and Bezos Dumping Stocks
The world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.tc pixel
Verve Therapeutics Announces Merger and Nasdaq Delisting
See More Headlines

VERV Stock Analysis - Frequently Asked Questions

Verve Therapeutics, Inc. (NASDAQ:VERV) announced its earnings results on Wednesday, May, 14th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.36. The company earned $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. Verve Therapeutics had a negative net margin of 303.64% and a negative trailing twelve-month return on equity of 35.81%.

Verve Therapeutics (VERV) raised $201 million in an IPO on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO.

Verve Therapeutics' top institutional shareholders include Alphabet Inc. (13.65%), Alpine Associates Management Inc. (3.07%), Hudson Bay Capital Management LP and Hudson Bay Capital Management LP. Insiders that own company stock include Krishna Yeshwant, Andrew D Ashe, Sekar Kathiresan, Joan Nickerson, Allison Dorval, Andrew Bellinger and 2017 Gp LLC Gv.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verve Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
5/14/2025
Today
8/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VERV
CIK
1840574
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$24.00
Low Price Target
$11.00
Potential Upside/Downside
+30.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$198.71 million
Net Margins
-303.64%
Pretax Margin
-303.10%
Return on Equity
-35.81%
Return on Assets
-27.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.84
Quick Ratio
9.84

Sales & Book Value

Annual Sales
$32.33 million
Price / Sales
30.69
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.83 per share
Price / Book
1.91

Miscellaneous

Outstanding Shares
89,140,000
Free Float
71,938,000
Market Cap
$992.13 million
Optionable
Optionable
Beta
2.23
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:VERV) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners